The GORAB Knockout HT29 Polyclonal Cells represent a CRISPR/Cas9-edited polyclonal knockout cell population derived from the HT29 colorectal adenocarcinoma cell line, engineered to disrupt the GORAB gene. This polyclonal pool provides a mixed population of edited cells, enabling loss-of-function studies without single-cell clonal selection. The product serves as a robust model for investigating GORAB-dependent cellular processes, with gene disruption achieved through general CRISPR/Cas9-mediated targeting, avoiding reliance on any specific clonal genotype.
The host HT29 cell line is a well-characterized human colorectal adenocarcinoma epithelial model harboring APC, TP53, and BRAF V600E mutations, with a microsatellite-stable background. Under glucose depletion, HT29 cells undergo differentiation, recapitulating aspects of intestinal epithelial architecture. This line is extensively used in colorectal cancer biology, intestinal barrier function studies, and drug transport research, making it an ideal context to examine the role of Golgi-associated proteins in epithelial homeostasis and oncogenic transformation.
GORAB encodes a trans-Golgi network scaffold protein critically involved in Golgi ribbon maintenance and microtubule nucleation. Mechanistically, GORAB interacts with the small GTPases RAB6A and RAB6B, the mitotic kinase PLK1, and components of the ??-tubulin ring complex such as TUBG1 and TUBGCP2, facilitating microtubule anchoring at the Golgi. GORAB also associates with the cis-Golgi matrix protein GM130 (GOLGA2) and is regulated by upstream Golgi stress signals and cell cycle cues. Disruption of GORAB leads to Golgi fragmentation, impaired microtubule organization, and defective ER-to-Golgi trafficking, thereby affecting downstream secretion of cargoes including collagens and glycosyltransferases. This network is further linked to Wnt signaling, where proper Golgi architecture influences the maturation and secretion of Wnt ligands.
In the HT29 colorectal cancer context, GORAB knockout provides a powerful tool to dissect the interplay between Golgi organization and oncogenic pathways. HT29 cells exhibit Wnt pathway hyperactivation due to APC mutation, and GORAB-dependent Golgi dynamics may modulate the subcellular distribution or activity of Wnt signaling components. Additionally, Golgi-mediated trafficking impacts the surface expression of drug transporters and receptors, potentially influencing sensitivity to chemotherapeutics like 5-fluorouracil and oxaliplatin. The HT29 model also permits functional evaluation of epithelial barrier integrity, as Golgi-derived polarity cues contribute to tight junction formation.
Researchers can employ these polyclonal knockout cells in diverse assays, including immunofluorescence staining for Golgi markers (GM130, TGN46) to assess morphological changes, transwell migration and wound healing assays to evaluate invasive properties, and real-time qPCR to measure Wnt target gene expression (AXIN2, MYC). The model is suitable for drug resistance profiling, transepithelial electrical resistance (TEER) measurements to study barrier function, and mechanistic investigations of Golgi stress responses. Moreover, it serves as a disease model for geroderma osteodysplasticum, a connective tissue disorder linked to GORAB mutations. For further information, please contact Ascent Research.
